Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics for people impacted by kidney disease. The company's mission is to better the lives of patients by leveraging hypoxia-inducible factor (HIF) biology to address unmet medical needs. Akebia Therapeutics is currently headquartered in Cambridge, Massachusetts, with plans to relocate its corporate headquarters to Waltham, Massachusetts in September 2026.

The company's commercial portfolio includes two FDA-approved products: Auryxia (ferric citrate) and Vafseo (vadadustat). Auryxia is approved in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease (DD-CKD) and for the treatment of iron deficiency anemia in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, is approved in Japan for the treatment of anemia due to CKD and received U.S. FDA approval in March 2023 for anemia due to CKD in adults on dialysis, with its U.S. launch in January 2025.

John Butler has served as the President and CEO since September 2013, guiding the company's strategic direction. Akebia Therapeutics recently expanded its pipeline by acquiring rights to AKB-097 (formerly ADX-097), a complement inhibitor, from Q32 Bio in December 2025, establishing a rare kidney disease pipeline. Phase 2 trials for AKB-097 and praliciguat (for focal segmental glomerulosclerosis, FSGS) are slated to begin treating subjects in 2026. The company reported a net income of $0.5 million in Q3 2025, marking a significant financial turnaround driven by the successful U.S. launch of Vafseo.